利用MRI预测初始不可切除结直肠癌肝转移患者转化治疗疗效:预测评分模型的开发
本研究回顾性纳入155例初始不可切除结直肠癌肝转移患者,在开发队列(n=104)中基于基线MRI特征建立预测转化成功率的评分模型mrNISE,并在验证队列(n=51)中验证。mrNISE评分在开发队列AUC为0.845、验证队列AUC为0.776,预测高转化成功率组无进展生存期和总生存期均优于低转化成功率组。
要点
- mrNISE评分基于基线MRI的4项特征:肝转移灶数目≥10个、最大径≥50 mm、肿瘤-肝界面不清、瘤周强化。
- 评分预测转化成功率的AUC在开发队列为0.845、验证队列为0.776。
- 按评分分层,预测高转化成功率组无进展生存期和总生存期均优于低转化成功率组。
核心结论
- mrNISE评分对初始不可切除结直肠癌肝转移的转化成功率具有较好的预测性能,可用于转化治疗前制定个性化治疗目标。
研究设计与样本
- 回顾性研究,共纳入155例连续初始不可切除结直肠癌肝转移患者,开发队列n=104、验证队列n=51,基于基线MRI特征采用多变量逻辑回归建立预测评分模型,以转化成功率为参考标准。
关键影像表现/征象
- mrNISE评分纳入的MRI特征包括肝转移灶数目≥10个、最大径≥50 mm、肿瘤-肝界面不清和瘤周强化。
诊断标准与关键数值
- mrNISE评分预测转化成功率的AUC在开发队列为0.845,在验证队列为0.776。
- 评分包含4项基线MRI特征:肝转移灶数目≥10个、最大径≥50 mm、肿瘤-肝界面不清、瘤周强化。
临床应用与阅片要点
- 可依据基线MRI的肝转移灶数目、最大径、肿瘤-肝界面和瘤周强化计算mrNISE评分,用于转化治疗前评估转化成功率。
- 按评分将患者分层为预测高转化成功率组和低转化成功率组,高转化成功率组无进展生存期和总生存期优于低转化成功率组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: The conversion success rate (CSR) has crucial implication for clinical outcomes of initially unresectable colorectal liver metastases (CRLM) following conversion therapy. This study aimed to develop a simple predictive scoring model for identifying CSR according to baseline magnetic resonance imaging (MRI) features, and confirm its performance and prognostic significance in a validation cohort.
METHODS: A total of 155 consecutive patients with initially unresectable CRLM were retrospectively reviewed in the study. A simple MRI-based predictive scoring model for identifying CSR was developed in the development cohort (n = 104) by using multivariable logistic regression analyzes. The diagnostic performance was evaluated for the predictive score. Thereafter, patients in the validation cohort (n = 51) were stratified into groups with predicted high CSR or low CSR according to the score. The progression-free survival (PFS) and overall survival (OS) were compared between two groups using the log-rank test.
RESULTS: The predictive score of CSR, named mrNISE, incorporated the number of CRLM ≥ 10, the largest size ≥ 50 mm, poorly defined tumor-liver interface, and peritumoral enhancement. The AUC of the mrNISE score was 0.845 for the development cohort and 0.776 for the validation cohort. According to the score, patients with predicted high CSR had better PFS and OS than those with low CSR in both development and validation cohorts.
CONCLUSION: The predictive score demonstrated great performance for identifying CSR of initially unresectable CRLM. Stratifying patients by the score, personalized treatment goals can be formulated before conversion therapy to improve clinical prognosis and reduce adverse events caused by ineffective treatment.
引用
- Liu J, Tang W, Ye L, et al. Estimating Efficacy of Conversion Therapy on Patients with Initially Unresectable Colorectal Cancer Liver Metastases by using MRI: Development of a Predictive Score. Acad Radiol. 2024. PMID: 38734578. doi:10.1016/j.acra.2024.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。